.jpg?format=webp&width=780)
A study showcases the benefits of HCL AHCL systems with Automated Mode SmartGuard in hospital settings for type I diabetes patients. The survey revealed that these systems lead to over 70% time in range (TIR) within 70—180 mg/dL without increased hypoglycemia. With 70.8% of patients achieving this TIR during hospitalization, no device-related severe adverse events occurred. AHCL with active SmartGuard showed even higher TIR and shorter hospital stays.
Like
Save
Share